-
公开(公告)号：US11648260B2
公开(公告)日：2023-05-16
申请号：US17042441
申请日：2019-03-27
Inventor： Shulamit Levenberg , Shaowei Guo , Daniel Offen , Nisim Perets
IPC: C07H21/02 , C07H21/04 , A61K31/713 , A61K35/28 , A61K38/51 , C12N15/113 , A61K9/50 , C12N15/11 , A61K9/127
CPC classification number: A61K31/713 , A61K9/5068 , A61K35/28 , A61K38/51 , C12N15/111 , C12N15/113 , C12N15/1137 , A61K9/127 , C12N2310/14 , C12N2310/3515 , C12N2310/531 , C12N2320/32
Abstract: The present invention provides pharmaceutical compositions comprising membrane vesicles, including extracellular vesicles including those referred to as exosomes, loaded with an exogenous Phosphatase and tensin homolog (PTEN) inhibitor. Methods of treating neurological diseases, disorders or conditions using the extracellular vesicles are provided. Isolated extracellular vesicles loaded with an exogenous Phosphatase and tensin homolog (PTEN) inhibitor are provided as well.
-
公开(公告)号：US20150259392A1
公开(公告)日：2015-09-17
申请号：US14433047
申请日：2013-03-05
Applicant: RAMOT AT TEL-AVIV UNIVERSITY LTD.
Inventor： Daniel Offen , Israel Aharony
IPC: C07K14/47
CPC classification number: C07K14/47 , A61K38/00 , C07K14/4703 , C07K14/8139 , C07K2319/10
Abstract: An isolated peptide comprising a Huntingtin (Htt) amino acid sequence being no longer than 15 amino acids, wherein said Htt amino acid sequence comprises the sequence X1X2X3X4 X5, wherein X1 is a hydrophobic amino acid or threonine, X2 is a hydrophobic amino acid, X3 is a hydrophobic amino acid, X4 is an acidic amino acid and X5 is selected from the group consisting of glycine, serine and alanine, the peptide capable of specifically inhibiting the activity of caspase 6.
Abstract translation: 一种分离的肽，其包含不超过15个氨基酸的亨廷丁（Htt）氨基酸序列，其中所述Htt氨基酸序列包含序列X1X2X3X4X5，其中X1是疏水性氨基酸或苏氨酸，X2是疏水性氨基酸，X3 是疏水性氨基酸，X4是酸性氨基酸，X5选自甘氨酸，丝氨酸和丙氨酸，能够特异性抑制胱天蛋白酶6活性的肽。
-
公开(公告)号：US11185572B2
公开(公告)日：2021-11-30
申请号：US16047129
申请日：2018-07-27
Inventor： Avinoam Kadouri , Avihay Bar-Ilan , Eldad Melamed , Daniel Offen , Ofer Sadan , Merav Bahat-Stromza
Abstract: An isolated human cell is disclosed comprising at least one mesenchymal stem cell phenotype and secreting brain-derived neurotrophic factor (BDNF), wherein a basal secretion of the BDNF is at least five times greater than a basal secretion of the BDNF in a mesenchymal stem cell. Methods of generating same and uses of same are also disclosed.
-
公开(公告)号：US11129852B2
公开(公告)日：2021-09-28
申请号：US16325445
申请日：2017-08-14
Applicant: RAMOT AT TEL-AVIV UNIVERSITY LTD.
Inventor： Daniel Offen , Nisim Perets
Abstract: A method of treating a neurological disease (such as autism) in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of microparticles derived from mesenchymal stem cells.
-
5.发明授权公开(公告)号：US10723706B2
公开(公告)日：2020-07-28
申请号：US16066697
申请日：2017-06-13
Applicant: Ramot at Tel-Aviv University Ltd.
Inventor： Gerardo Zelmar Lederkremer , Julia Leitman , Hagit Eiger , Daniel Offen , Javier Ganz , Moshe Portnoy
IPC: C07D239/42 , A61K45/06 , A61K31/505 , A61P25/00
Abstract: Compounds represented by Formula I are disclosed herein, wherein R, Ra and R1-R14 are as defined herein. Further disclosed are uses and methods utilizing said compounds for use in inhibiting an activity of PERK, and in treating a disease or disorder associated with aggregation-prone proteins, a disease or disorder in which downregulating an unfolded protein response is beneficial, and/or Huntington's disease.
-
Patent Agency Ranking
公开(公告)号：US09717761B2
公开(公告)日：2017-08-01
申请号：US14359623
申请日：2012-11-21
Applicant: RAMOT AT TEL-AVIV UNIVERSITY LTD.
Inventor： Sandu Pitaru , Javier Ganz , Daniel Offen , Eldad Melamed
IPC: C12N5/00 , A61K35/30 , C12N5/0793 , C12N5/079 , A61K35/12
CPC classification number: A61K35/30 , A61K2035/124 , C12N5/0619 , C12N5/0622 , C12N2500/38 , C12N2500/90 , C12N2501/01 , C12N2501/11 , C12N2501/115 , C12N2501/119 , C12N2501/13 , C12N2501/135 , C12N2501/41 , C12N2501/415 , C12N2501/999 , C12N2506/097
Abstract: The present invention provides methods and uses of neural cells differentiated from adult stem cells of the oral mucosa for cell therapy of neurological and psychiatric diseases and disorders. Methods for direction of differentiation of oral mucosal stem cells into neuronal or neuron supporting cells are also provided.
-
公开(公告)号：US20150086517A1
公开(公告)日：2015-03-26
申请号：US14556281
申请日：2014-12-01
Inventor： Avinoam Kadouri , Avihay Bar-Ilan , Eldad Melamed , Daniel Offen , Ofer Sadan , Merav Bahat-Stromza
IPC: A61K38/18
CPC classification number: A61K38/185 , A61K35/12 , A61K35/28 , C12N5/0618 , C12N5/0662 , C12N5/0663 , C12N5/0664 , C12N5/0665 , C12N5/0666 , C12N5/0667 , C12N5/0668 , C12N5/0669 , C12N2500/84 , C12N2501/01 , C12N2501/11 , C12N2501/115 , C12N2501/135 , C12N2506/1353
Abstract: An isolated human cell is disclosed comprising at least one mesenchymal stem cell phenotype and secreting brain-derived neurotrophic factor (BDNF), wherein a basal secretion of the BDNF is at least five times greater than a basal secretion of the BDNF in a mesenchymal stem cell. Methods of generating same and uses of same are also disclosed.
Abstract translation: 公开了一种分离的人细胞，其包含至少一种间充质干细胞表型和分泌性脑源性神经营养因子（BDNF），其中BDNF的基础分泌比间充质干细胞中BDNF的基础分泌高至少五倍 。 还公开了生产方法及其用途。
-
8.发明授权公开(公告)号：US11104651B2
公开(公告)日：2021-08-31
申请号：US16920710
申请日：2020-07-05
Applicant: Ramot at Tel-Aviv University Ltd.
Inventor： Gerardo Zelmar Lederkremer , Julia Leitman , Hagit Eiger , Daniel Offen , Javier Ganz , Moshe Portnoy
IPC: A61K45/06 , A61K31/505 , A61P25/00 , C07D239/42
Abstract: Compounds represented by Formula I are disclosed herein, wherein R, Ra and R1-R14 are as defined herein. Further disclosed are uses and methods utilizing said compounds for use in inhibiting an activity of PERK, and in treating a disease or disorder associated with aggregation-prone proteins, a disease or disorder in which downregulating an unfolded protein response is beneficial, and/or Huntington's disease.
-
公开(公告)号：US10744162B2
公开(公告)日：2020-08-18
申请号：US16353680
申请日：2019-03-14
Inventor： Daniel Offen , Michal Dadon-Nachum , Tali Ben-Zur , Eldad Melamed , David Yaffe
Abstract: An isolated muscle progenitor cell being MyoD positive, CD34 negative and CD45 negative is disclosed. The muscle progenitor cell is genetically modified to express at least one neurotrophic factor. In addition, cell populations are disclosed, comprising at least four subpopulations of muscle cells each being genetically modified to express a different neurotrophic factor, wherein said neurotrophic factor is selected from the group consisting of glial derived neurotrophic factor (GDNF), insulin growth factor (IGF-1), vascular endothelial growth factor (VEGF) and brain-derived neurotrophic factor (BDNF). Uses of the cell populations are also disclosed.
-
公开(公告)号：US09879225B2
公开(公告)日：2018-01-30
申请号：US14173846
申请日：2014-02-06
Applicant: Ramot at Tel-Aviv University Ltd.
Inventor： Daniel Offen , Merav Bahat-Stromza , Eldad Melamed
CPC classification number: C12N5/0669 , C12N5/0622 , C12N2501/11 , C12N2501/115 , C12N2501/135 , C12N2501/40 , C12N2506/1353
Abstract: An isolated human cell and populations thereof is provided comprising at least one astrocytic phenotype and at least one mesenchymal stem cell phenotype, wherein the mesenchymal stem cell phenotype is not an astrocytic phenotype.
-
-
-
-
-
-
-
-
-
Search Results
20
records
(took 0.021 seconds)
